Floatz logo

2-AMINO-5-(4-(((2R)-2-(3,5-DIFLUOROPHENYL)-2-HYDROXYACETYL)AMINO)-2-METHYLPHENYL)-N-(1-METHYLETHYL)-3-PYRIDINECARBOXAMIDE

Small-cell Lung Cancer

HiberCell, Inc.Small moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

291 Active assets in the Small-cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
vx-970
National Cancer Institute (NCI)
Phase 2BBB
Adebelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BBB
Veliparib
Central European Society for Anticancer Drug Research
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

2-AMINO-5-(4-(((2R)-2-(3,5-DIFLUOROPHENYL)-2-HYDROXYACETYL)AMINO)-2-METHYLPHENYL)-N-(1-METHYLETHYL)-3-PYRIDINECARBOXAMIDE is also rated in:

Other Solid TumorsDormant
CC
Indicative ·
44 / 100
View asset →
breast cancerDormant
CC
Indicative ·
42 / 100
View asset →
renal cell carcinomaDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →